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Abstract
Mycobacterium ulcerans infection causes a neglected tropical disease known as Buruli ulcer that is now found in poor rural
areas of West Africa in numbers that sometimes exceed those reported for another significant mycobacterial disease,
leprosy, caused by M. leprae. Unique among mycobacterial diseases, M. ulcerans produces a plasmid-encoded toxin called
mycolactone (ML), which is the principal virulence factor and destroys fat cells in subcutaneous tissue. Disease is typically
first manifested by the appearance of a nodule that eventually ulcerates and the lesions may continue to spread over limbs
or occasionally the trunk. The current standard treatment is 8 weeks of daily rifampin and injections of streptomycin (RS).
The treatment kills bacilli and wounds gradually heal. Whether RS treatment actually stops mycolactone production before
killing bacilli has been suggested by histopathological analyses of patient lesions. Using a mouse footpad model of M.
ulcerans infection where the time of infection and development of lesions can be followed in a controlled manner before
and after antibiotic treatment, we have evaluated the progress of infection by assessing bacterial numbers, mycolactone
production, the immune response, and lesion histopathology at regular intervals after infection and after antibiotic therapy.
We found that RS treatment rapidly reduced gross lesions, bacterial numbers, and ML production as assessed by cytotoxicity
assays and mass spectrometric analysis. Histopathological analysis revealed that RS treatment maintained the association of
the bacilli with (or within) host cells where they were destroyed whereas lack of treatment resulted in extracellular infection,
destruction of host cells, and ultimately lesion ulceration. We propose that RS treatment promotes healing in the host by
blocking mycolactone production, which favors the survival of host cells, and by killing M. ulcerans bacilli.
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Introduction
Mycobacterium ulcerans infection is the cause of the neglected
tropical disease, Buruli ulcer, found in poor rural areas of West
Africa as well as in beach resorts in Australia [1] principally,
although transmission has occurred in every continent except
Europe. It is the third most important mycobacterial infection of
humans worldwide after tuberculosis and leprosy, although in
Benin and Ghana, for example, it is now the second most common
mycobacterial disease [2,3]. Infection begins after exposure in
slow-moving fresh water to plants or biting insects or other
unknown mechanisms and slowly leads to swelling, manifested as a
nodule, plaque, or edema in humans, and in experimental animals
[4,5,6,7,8]. Untreated lesions may progress and involve an entire
limb or the trunk. Part of the pathogenic process is the production
of the immunosuppressive mycolactone (ML) toxin by M. ulcerans
that promotes the development of necrotic ulcers and possibly the
initial swelling. How soon ML production begins after infection is
unknown [9] as is how soon it stops due to antibiotic treatment,
currently rifampin and streptomycin [1], although studies of
human lesions have suggested production may be affected soon
after treatment [10].
Evidence from the mouse model indicates that BALB/c mice
develop swelling accompanied by increasing bacterial burden as
measured by CFU followed by a plateau in CFU but progression
of swelling [4,11,12]. After antibiotic treatment, both swelling and
CFU decline [13].
We evaluated the evolution of M. ulcerans (Mu1615, Malaysian
strain) infection in the mouse footpad model by assessing not only
lesion appearance and CFU number, but also ML production,
systemic immune responses, and histopathology at different times
after infection and after the onset of antibiotic therapy. We find
that the current standard antibiotic therapy started after the
appearance of swelling not only reduces bacterial load but also
preserves an effective host cell infiltrate leading to loss of acid-fast
stain integrity of the bacilli. The host immune response was tested
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in splenocytes stimulated with mycobacterial antigens and assessed
by measuring cytokine and chemokine production. Additionally,
there is an early and continuing restraint on ML production that
may help the host control and reduce bacillary numbers.
Materials and Methods
Bacteria
M. ulcerans 1615 (Mu1615), an isolate originally obtained from a
patient in Malaysia in the 1960s, [14] was kindly provided by Dr.
Pamela Small, University of Tennessee. Previous studies have
confirmed that this strain produces mycolactone and kills
macrophages and fibroblasts [15,16]. The strain was passaged in
mouse footpads before use in these studies. The bacilli were
harvested from swollen footpads at the grade 2 level, i.e., swelling
with inflammation of the footpad [4].
Infection and CFU/histopathology/immunology analyses
BALB/c mice, age 4–6 weeks (Charles River, Wilmington,
MA), were inoculated in the right hind footpad with approxi-
mately 5.5 log10 (3610
5) CFUs of Mu1615 in 0.03 ml PBS.
Footpads were harvested from 9 mice (3 for CFU count, 3 for ML
detection, 3 for histopathology) at different time points after
infection (Table 1) up to $grade 3 swelling. After the onset of
swelling (,day 21–23), treatment with rifampin (R, Sigma, St.
Louis, MO, 10 mg/kg by gavage) and streptomycin (S, Sigma,
150 mg/kg by subcutaneous injection) began on day 24, and was
administered 5 days/week for 8 weeks. Groups of the treated mice
were also sacrificed for these analyses. For CFU counts footpad
tissue was harvested, minced with fine scissors [17], suspended in
2.0 ml PBS, serially diluted, and plated on Middlebrook selective
7H11 plates (Becton- Dickinson, Sparks, MD). Alternatively,
footpads were harvested and placed in 10% buffered formalin for
histopathological analysis by hematoxylin and eosin (H&E) or
acid-fast (AF) staining. Footpads from a third group of mice at
each time point were placed in freezer vials and frozen at 280uC.
These latter footpads were shipped on dry ice to St. George’s
University of London for mycolactone detection experiments.
Mice were evaluated for footpad swelling weekly using an
established scoring system [4] with grade 1 showing footpad
swelling, grade 2 swelling with inflammation, and grade 3 swelling
and inflammation of the entire foot [18]. Spleens were harvested
to assess responses to mycobacterial culture filtrate proteins (CFP)
and to the concanavalin A (ConA) mitogen (Sigma) by multiplex
ELISA (Bio-Plex Pro Mouse Cytokine 23-plex Assay, Biorad,
Hercules, CA) as described [15]. The 23 analytes included Th1
cytokines: IL-2, IFN-c, IL-12p40, IL-12p70; Th2 cytokines: IL-4,
IL-5, IL-10, and IL-13; proinflammatory cytokines: TNF-a, IL-
1a, IL-1b, and IL-6; IL-9; IL-17; colony stimulating factors:
GMCSF, GCSF, IL-3; and chemokines: CXCL-1, CCL-2, CCL-
3, CCL-4, CCL-5, and CCL-11. All animal procedures were
conducted according to relevant national and international
guidelines. The study was conducted adhering to the Johns
Hopkins University guidelines for animal husbandry and was
approved by the Johns Hopkins Animal Care and Use Committee,
protocol MO08M240. The Johns Hopkins program is in
compliance with the Animal Welfare Act regulations and Public
Health Service (PHS) Policy and also maintains accreditation of its
program by the private Association for the Assessment and
Accreditation of Laboratory Animal Care (AAALAC) Interna-
tional.
Mycolactone detection assays
Extraction of lipids frommouse footpads for mycolactone
detection and quantification. Mouse footpads were weighed,
diced with a scalpel blade and homogenised in 500 ml extraction
solution of chloroform: methanol 2:1 vol/vol with ceramic beads
in a Fastprep ribolyser at power 6.5 for 45 seconds and again at
power 5.0 for 45 seconds [19]. After homogenisation, an
additional 500 ml of extraction solution was added and samples
were placed on ice for 4 hours. 0.2 ml of 0.3% sodium chloride
solution was added for Folch’s extraction and samples were
centrifuged at 13,000 g for 5 minutes. The organic phase was
harvested, dried down under vacuum and lipids re-suspended in
ice-cold acetone for an hour and centrifuged at 13,000 g for
5 minutes to remove phospholipids. Acetone soluble lipids (ASL)
were dried down under vacuum and re-suspended in 100%
ethanol.
Cytotoxicity assay for mycolactone quantification. Cy-
totoxicity of ASL from infected mouse tissue was tested using the
MTT assay, a colorimetric test assessing cellular viability, as
previously described [20,21]. Briefly, HELF cells (kindly donated
by Dr. Kay Capaldi) were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum and
2 mM L-glutamine in the presence of penicillin and streptomycin
100 mU/ml and 100 mg/ml respectively and incubated in 5%
carbon dioxide at 37uC. For cytotoxicity assays proliferating
HELF cells were seeded at a density of 105/well in microtiter
plates overnight.
ASL were dissolved in 100 ml of absolute ethanol and 2-fold
dilutions performed up to 1:32. 5 ml of each dilution was used to
treat HELF cells in triplicate. After incubation for 48 hrs, 20 ml of
5 mg/ml of MTT (Sigma) was added to each well and incubated
for a further 4 h for purple colored formazan crystals to develop
following which 100 ml of detergent solution of isopropanol:HCl
(2N) in a ratio of 49:1 was used to dissolve formazan crystals for
spectrophotometric quantification in a multiplate well reader at
570–690 nm. Time course and dose-response curves were derived
by treating HELF cells with serial dilutions of purified mycolac-
tone A/B from 250 ng/ml to 0.3 ng/ml (kind gift of Professor Y.
Kishi, Harvard University, USA]. All calibration and quantifica-
tion experiments were performed at least twice. Concentration of
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Mycobacterium ulcerans infection causes Buruli ulcer (BU), a
disfiguring skin disease now found principally in poor rural
areas of West Africa. M. ulcerans produces a toxin called
mycolactone (ML), which destroys fat cells in skin tissue.
BU typically first shows as a nodule that eventually
ulcerates. The lesions may continue to spread over limbs
or occasionally the trunk. The current standard treatment
is 8 weeks of daily rifampin and injections of streptomycin
(RS). The treatment kills the bacilli and wounds gradually
heal. We tried to determine if RS treatment actually stops
mycolactone production before killing bacilli. Using a
mouse footpad model of M. ulcerans infection where the
time of infection and lesion development can be followed
in a controlled manner before and after antibiotic
treatment, we found that RS treatment rapidly reduced
footpad swelling, M. ulcerans numbers, and ML produc-
tion. Microscopic analysis of footpads revealed that RS
treatment resulted in bacilli being destroyed by host cells
whereas lack of treatment resulted in extracellular infec-
tion, destruction of host cells, and lesion ulceration. We
propose that RS treatment promotes healing in the host
by blocking mycolactone production, which favors the
survival of host cells, and by killing M. ulcerans.
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mycolactone was determined within the linear portion of the dose
response curve since cytotoxicity followed a sigmoidal dose-
response relationship.
Mass spectroscopy. Serial dilutions of synthetic mycolac-
tone A/B standards from 80 ng/ml to 1.25 ng/ml and ethanolic
lipid extracts diluted 1:10 in 96-well plates (Nunc) and liquid
chromatographic separation and tandem mass spectrometric
detection were performed using an ABI Sciex 3200 Q Trap mass
spectrometer (ABI Sciex, UK) interfaced with a Shimadzu UFLC
system (UFLC XR system with CBM-20A controller, SIL-20AC
XR Prominence autosampler, CTO-20AC Prominence column
oven, LC-20AD XR and LC-20 AD pumps (Shimadzu, UK)).
Mycolactone A/B was characterized by Enhanced Product Ion
(EPI) detection. EPI conditions were optimized by infusing a 1 mg/
mL ethanolic solution of mycolactone A/B standard via a Harvard
syringe pump at flow rate of 10 mL/min. Characteristic ions in
mycolactone A/B EPI spectra were m/z 765.5 [M+Na+], 429.3
and 359.2. EPI parameters for mycolactone A/B were: decluster-
ing potential (DP) 20V, entrance potential (EP) 10V, collision cell
entrance potential (CEP) 32.35V and collision energy (CE) 65 eV.
Mycolactone was quantified by Multiple Reaction Monitoring
(MRM). MRM transitions of mycolactone were identified by the
compound optimization tool in Analyst 1.5 during the infusion of
1 mg/mL mycolactone A/B standard. From these, MS-MS
fragmentation of the mycolactone A/B sodium adduct [M+Na+]
(m/z 765.5, Q1 mass) to m/z 429.3 (Q3 mass) was selected for
quantification. MRM parameters were dwell time 150 ms, DP
126V, EP 10V, CEP 34V, CE 57 eV, cell exit potential (CXP) 6V.
Source parameters for LC-MS-MS were: curtain gas 30 psi,
collision gas medium, ion spray voltage 5500 V, temperature
400uC, nebulizer gas 30 psi, turbo gas 40 psi.
For the analysis of lipid extracts from mouse footpads, UPLC
was combined with EPI methods (LC-EPI) or MRM methods
(LC-MRM). Solvent A was 0.1% formic acid and 10-mM
ammonium acetate in water. Solvent B was 0.1% formic acid
and 10-mM ammonium acetate in acetonitrile. Samples (10 mL)
were injected via autosampler and eluted at 0.5 mL/min on a
Shima-Pack XR-ODS II column (2.1 mm, 2.0 mm675 mm) by a
20–98% linear gradient of B over 2 min. Solvent composition was
then held for 4 min before returning to the starting conditions.
Standard curves (1.25 ng/mL to 100 ng/mL) were prepared using
ethanolic stock solutions of synthetic mycolactone A/B.
Statistical analysis
GraphPad Prism 4 was used to assess significant differences by
student T and analysis of variance.
Results
Footpad swelling and CFU counts before and after
treatment
Three days after infection, mice harbored 3.2960.33 log10 CFU
in the infected footpads. Just before the onset of swelling, at day
20, the footpads contained 5.0560.19 log10 CFU of M. ulcerans.
Footpad swelling first appeared in some mice 3 weeks after
infection and averaged grade 1 soon after the initiation of
treatment at ,3.5 weeks after infection. At day 27, there were
approximately 6.0260.13 log10 CFU per footpad. Swelling
continued to increase over the following 3 weeks (Figure 1) for
an average of grade 3.4260.43 in untreated mice whereas CFU
counts remained essentially unchanged. In contrast, both swelling
and CFU counts declined markedly in the RS-treated mice.
Swelling after 3 weeks of treatment averaged grade 0.1460.18 and
log10 CFU count per footpad was reduced to 0.5260.45. By day
55 after infection, untreated mice had 6.3760.32 log10 CFU
whereas RS-treated mice, at this time point after 31 days of
treatment, had only 0.2060.35 log10 CFU (Figure 2a). By day 63
(i.e., 39 days of treatment), the RS-treated mice were culture
negative. Swelling was essentially undetectable. Figure 2b shows
the contrast in M. ulcerans CFU counts between treated and
untreated mice.
Histopathological assessment of M. ulcerans in lesions
before and after treatment
Histologically, increased numbers of AFB correlated with
increased footpad swelling in untreated mice; bacilli were evident
initially in the dermis and eventually in sub-epidermal zones and
the epidermis with the onset of ulceration (Figure 3A.1–5).
Inflammatory cell infiltrates appeared to be maintained in RS-
treated mice but were disrupted and progressively disorganized in
untreated, control mice (Figure 3B.1–4). After 2–3 weeks of
treatment, AFB were still detectable but acquired a beaded
appearance and this morphology persisted even after treatment
completion. The beaded appearance of the bacilli correlated with
reduced numbers of cultivable bacilli in treated mice (Figure 2)
Table 1. Scheme of study.
Day 3 7 13 20 27 34 40 48 55 62 70 78 98 Total
Control mice
CFU 3 3 3 3 3 3 3 3 3 27
Mycolactone 3 3 3 3 3 3 3 3 3 3 30
Histopathology 3 3 3 3 3 3 3 3 3 27
Treated mice
CFU 3 3 3 3 3 3 3 3 24
Mycolactone 3 3 3 3 3 3 18
Histopathology 3 3 3 3 3 3 18
Total 9 9 9 9 18 18 18 18 18 9 3 6 144
Control and treated (i.e., Rifampin, 10 mg/kg, and streptomycin, 150 mg/kg) mice were sacrificed at the indicated days after infection for CFU analysis, mycolactone
detection, immunological assessment, or histopathology. Treatment began on day 24 after infection.
doi:10.1371/journal.pntd.0002101.t001
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whereas the bacilli in untreated mice appeared solidly stained.
Three months after treatment completion, bacilli were detectable
in tissue by acid-fast staining but were not cultivable (Figure 3B.5).
Evolution of immune responses during the course of M.
ulcerans infection
ConA and CFP of M. tuberculosis (Mtb) were used as a potent T-
cell mitogen and a non-specific mycobacterial antigen, respective-
ly, to both assess the functional capability of T-cells and the
evolution of cellular immune responses by splenocytes to
mycobacterial antigens during the course of M. ulcerans infection.
There is a biphasic pattern to the kinetics of secretion of
representative Th-1 (IFN-c), Th-2 (IL-5) and Th-17 (IL-17)
cytokines upon stimulation with the potent T-cell mitogen ConA
(Figure 4, left column). There is an initial rise detected at week 2,
then a decline during weeks 4 to 6 and then a later surge from
week 7 onwards. The cellular responses to a culture filtrate protein
of Mtb however is generally a slowly evolving one and gradually
builds up (IL-2, IL-5, IFN-c and TNF-a) over the course of
infection with M. ulcerans (Figure 4, right column). Immune
responses were, however, generally lower during the course of
infection in mice treated with antibiotics compared with untreated
mice (Figure 4). Although the amount of TNF-a detected in
supernatants of splenocytes from mice treated with RS was much
less after 10 days of treatment, it was statistically significant
(p,0.001) only at day 55 by two-way ANOVA. A t-test analysis
indicated borderline statistical significance (p,0.05) at day 48.
The presence of mycolactone in footpads before and
after treatment
Mycolactone toxin production was assessed by two different
methods: cytotoxicity against the HELF cell line and mass
spectrometric analysis.
Cytotoxicity assay of lipid extracts from mouse
footpads. Lipid extracts from the right footpads into which
M. ulcerans had been injected were increasingly cytotoxic from day
Figure 1. After reaching plateau in bacillary numbers, M.
ulcerans-infected mouse footpads continue to increase in
swelling. Swelling first became apparent at day 20 after infection.
For the first 3 weeks, the number of cultivable organisms increased
from 3.2960.33 log10 on day 3 to 4.2660.08 log10 on day 7, 4.7360.42
log10 on day 13, 5.0560.19 log10 on day 20, and 6.0260.13 log10 on day
24, the first day of treatment. CFU remained at approximately this level
for the remainder of the experiment in untreated mice. Swelling
averaged ,grade 1 at day 27 after infection, nearly grade 2 at day 34,
grade 2.67 at day 40, 3.42 at day 48, 3.75 at day 55, 3.58 at day 63, and
3.75 again at day 78. Data based on 3 mice per group per time point.
Red lines emphasize the period between the onset and augmentation
of swelling and the plateau in CFU.
doi:10.1371/journal.pntd.0002101.g001
Figure 2. Swelling and CFU Reduction after RIF-STR treatment. After 3 days of RIF-STR (RS) treatment (day 27 after infection), swelling
averaged grade 1, and then declined to 0.6160.33, 0.2760.18, 0.1460.18, 0, 0.0660.17, and 0 on days 34, 40, 48, 44, 63, and 78, respectively. CFU also
declined from 6.0260.09 log10 on day 27, and then 3.8360.56 log10, 2.8260.49 log10, 0.5260.45 log10, 0.260.35 log10, 0, and 0 on days 34, 40, 48, 44,
63, and 78, respectively. For comparison, CFU per footpad for untreated controls (black line) show the impact of antibiotic treatment on bacterial
burden. Data based on 3 mice per group per time point.
doi:10.1371/journal.pntd.0002101.g002
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3 up to day 62. Surprisingly, lipid extracts from the left footpad of
the same mice also demonstrated significant cytotoxicity (Figure 5).
Lipid extracts from footpads of mice which had not been infected
with M. ulcerans showed median cytotoxicity of 20%, suggesting
that cytotoxicity observed in M. ulcerans-infected mice was due to
the presence of a cytotoxic molecule with activity similar to, or
targeting the same pathway as, mycolactone.
The mean concentration, as estimated in the cytotoxicity assay,
of mycolactone in the right footpad (3 per group) increased from
2866105 ng/ml at day 3 to 9486215 ng/ml at day 7, plateaued
between day 13 and 35 and progressively increased to
36036478 ng/ml at day 62 (Figure 5). In the left footpad of mice
infected on the right, the concentration also increased up to day 62
with a peak of 15246607 ng/ml at day 27. In the right and left
footpads of antibiotic treated mice, there was a significant decline
in estimated mycolactone concentration compared to untreated
right footpads (p,0.05 at day 62). Likewise, there was a significant
difference (p,0.02) in cytotoxicity between the right and the
contralateral footpads obtained from untreated mice.
Mass spectroscopic analysis. In order to establish whether
cytotoxicity in infected mouse footpads was due to whole
mycolactone molecules, liquid chromatography was coupled to
mass spectroscopic detection of mycolactone A/B. Using an
enhanced product ion (EPI) method, mycolactone A/B was
detected as an ion with m/z of 765.7 which fragmented to give
peaks at 429.5 (core lactone ring), 359.5 (polyketide side chain) and
other minor peaks at 747.7, 659.6 and 565.6 (Figure 6 A–D).
Using this approach, intact mycolactone A/B was identified in the
infected right footpad pools at day 13 onwards but not in the
uninfected left footpads.
An approximate quantification of mycolactone A/B was
achieved using multiple reaction monitoring (MRM). (Figure 6E).
In the infected right footpads, mycolactone A/B concentration
increased from 1.6 ng/ml on day 13 to a peak of 195.6 ng/ml on
day 62. In antibiotic treated mice mycolactone concentration in
the right footpads decreased from a peak of 23.7 ng/ml on day 35
to 1.6 ng/ml on day 62. No mycolactone was detected in left
footpads.
Conclusions
Our results show that RS treatment of experimental M. ulcerans
disease results not only in the reduction or elimination of viable
bacteria but also in clinical and histopathological improvement of
lesions, supporting results obtained in the analysis of human
specimens [22,23] and in RS-treated mice [24,25,26]. The
inflammatory response is also down-regulated with reduced
production of cytokines such as TNF-a during treatment. By
mass spectrometric analysis, mycolactone was detectable before
the observation of swelling and increased markedly and contin-
uously after swelling onset whereas M. ulcerans CFU counts peaked
and remained on a plateau. RS treatment resulted in a parallel loss
of cultivable M. ulcerans in the footpad lesions, a decline in footpad
swelling and an abrupt decline in the production of mycolactone
within days of treatment initiation.
Discussion
The initial clinical response to infection with M. ulcerans is
typically not strikingly different from the course of infection with
M. marinum [27,28,29,30]; a nodule develops in both cases but,
with M. ulcerans, there is an absence of tenderness and erythema.
The absence of pain and an inflammatory response is attributed to
the production of mycolactone inhibiting the immune response
[31], damaging nerves [32,33] and/or destroying infiltrating
inflammatory cells [34,35]. At which point in the course of
infection sufficient mycolactone is present to mediate these effects
cannot be readily ascertained in humans but can be approached in
the mouse model. The mouse model is also suitable to monitor the
impact on mycolactone production of antibiotic treatment, which
is thought to block mycolactone production and to reverse local
immunosuppression leading to the restoration of an active
inflammatory process [36].
In the experiment reported here, mycolactone was detectable 2
to 3 weeks after inoculating approximately 4.6 log10 CFU of M.
ulcerans into mouse footpads and before detectable swelling of the
footpads. The numbers of bacilli at the beginning of a human
infection are unknown but presumably considerably less. A
sensitive assay that would be appropriate for use in endemic
settings could conceivably detect infection before the nodular
phase or confirm the diagnosis of M. ulcerans infection in nodular
or plaque lesions before the onset of ulceration. Treatment with
the current gold standard of rifampin and streptomycin appears to
result in inhibition of mycolactone production. Whether the
inhibition blocks the pathway of enzymes encoded by the M.
ulcerans giant plasmid or has an impact on the plasmid itself has not
been assessed here but it could be investigated using samples
where there are still cultivable bacilli but negligible mycolactone
production. Mechanistically, streptomycin and rifampicin inhibit
protein synthesis by different mechanisms but they both result in a
decrease in bacterial viability and, directly or indirectly, in a
decrease of mycolactone production.
By sampling mouse footpads on a weekly basis we have been
able to confirm the early phagocytic, intracellular phase of M.
ulcerans infection followed by a later extracellular phase [26]. One
week after infection (Fig. 3A2), there was moderate infiltration of
host cells and bacilli were predominantly intracellular, an
observation made by Ruf et al. [25]. The extracellular phase of
bacillary growth appeared to coincide with the onset of footpad
swelling, beginning about 3 weeks after infection in this
experiment. Over the next two weeks, AFBs were increasingly
found outside of cells. The shift to an extracellular growth was
Figure 3. M. ulcerans in mouse footpads, before (A, 1–5) and after (B, 1–5) treatment with Rifampin-Streptomycin. A1: AFB are
detectable in the dermis 3 days after infection with little or no cellular infiltrate. 5006Magnification A2: At day 7, the migration of inflammatory cells
and phagocytosis has begun. 5006 Magnification A3: By day 13, AFB are primarily associated with inflammatory and phagocytic cells. 10006
Magnification A4: At day 20, the extracellular phase of M. ulcerans infection has begun, coinciding with the onset of footpad swelling. 10006
Magnification A5: At day 27, shortly after the initiation of antibiotic treatment, a mix of intracellular and extracellular AFB is observed. 5006
Magnification In panel B, untreated footpad lesions are shown on the left and treated footpads are shown on the right. B1: At day 34 after infection
and after 10 days of treatment, M. ulcerans bacilli in treated mice are primarily associated with host cells whereas the bacilli are outside of cells in
untreated mice; the cells are either not recruited or may have been destroyed by the mycolactone toxin. 5006, inset 10006, Magnification, B2: At day
40, bacilli are found in extracellular masses in untreated mice but in mice treated for 16 days, the bacilli are still associated with host cells and stain
less solidly. 5006, inset 10006, Magnification B3: At day 48, after 24 days of treatment, the bacilli have lost solid staining and have become beaded in
appearance. 5006, inset 10006, Magnification B4: At day 55 after infection, M. ulcerans bacilli are apparent in the superficial dermis and epidermis
and are being shed from the ulcerated lesions of untreated mice. 5006, inset 10006, Magnification B5: 3 months after treatment completion, the
organisms are uncultivable but non-solid staining bacilli are still present in the footpads. 5006Magnification.
doi:10.1371/journal.pntd.0002101.g003
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Figure 4. Cytokine production responses to concanavalin A or mycobacterial protein before and after Rifampin-Streptomycin
treatment. The dotted line indicates the levels in uninfected control (UIC) mice. Responses by untreated mice are indicated by solid bars and those
by rifampin-streptomycin (RS) treated mice are indicated by hatched bars. Responses of splenocytes stimulated with Concanavalin A (ConA) are in the
left column and with mycobacterial culture filtrate proteins (CFP) in the right column for representative cytokines, from top to bottom, IL-2, IFN-c, IL-
5, IL-17, and TNF-a. Data based on 3 mice per group per time point.
doi:10.1371/journal.pntd.0002101.g004
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blocked by treatment with rifampin and streptomycin, consistent
with the notion that mycolactone production and phagocyte
destruction are inhibited by antibiotic treatment [22,23,24]. In the
absence of treatment, the location of bacterial clusters also
changed from relatively deep in the dermis to sub-epidermal
and epidermal zones to the skin surface with the onset of footpad
ulceration. In contrast, in mice treated with the antibiotics, M.
ulcerans was found in a few clusters associated with phagocytic cells
within the dermis. The appearance of the bacteria became beaded
with less intense acid-fast staining [22,23,24,25], comparable to
the changes observed in the morphological index of leprosy bacilli
after the onset of treatment. At 3 months after the completion of 8
weeks of daily treatment, pale-staining bacilli were still detectable
and associated with host cells in the dermis but remained
uncultivable, suggesting that residual antigenic components may
have helped maintain an inflammatory infiltrate. Overall, from the
literature [25,34,37], we find that early after infection, there is a
dynamic picture of infiltrating host cells and bacillary localization
within phagocytic cells. When the same time points were
examined in mouse footpads on day 7 (this study and [25]) and
day 13 (this study and [34]), the histological impressions were
strikingly similar.
In this experiment, we observed increases in M. ulcerans CFU
counts starting at day 3 (3.2960.33 log10) and continuing to day
27 (6.0260.13 log10) after infection. The CFU counts remained at
approximately 6 log10 for the duration of the experiment through
day 55, after which time the footpads started to ulcerate and could
not be readily decontaminated for further analysis, given the
prolonged culture time for this organism (8–12 weeks). Swelling
was not apparent until day 20 in some mice, but by days 24 and
27, it averaged grade 1. Swelling continued to increase during this
time, while CFU counts were stable, and peaked only at day 55 at
an average of swelling grade 3.75. The fact that mycolactone
concentration continued to rise after the plateau in cultivable
organisms suggests that there was equilibrium between living and
dying M. ulcerans cells with mycolactone being released by both
populations. Alternatively, or in addition, mycolactone may be
induced by a quorum sensing mechanism as bacterial numbers
reach the plateau stage. Concurrently, or slightly before the
manifestation of swelling, mycolactone could be detected by mass
spectrometric analysis at day 13 (1.6 ng/ml of homogenized
footpad extract) and 4.18 ng/ml on day 20. In untreated mice the
concentration of mycolactone in infected footpads continued to
rise throughout the experiment. In mice treated with antibiotics
from day 24, mycolactone concentration tailed off after day 35 but
it did not become undetectable by MS until day 63. This suggests
either that viable organisms persisted for more than 5 weeks after
antibiotics were started or that mycolactone could still be detected
some time after M. ulcerans had been killed. The latter is supported
by the observations that no viable M. ulcerans were detected in
mouse footpads after antibiotic treatment, similar to that used
here, followed by a course of corticosteroid therapy [24,38] but we
did not use the very recently described 16S rRNA assay to
determine if viable organisms were still present [39].
Using the cytotoxicity assay, biological activity associated with
mycolactone was detectable as early as day 3 and persisted even at
day 63 despite antibiotic treatment. Although it is possible that this
assay is more sensitive than MS, experiments in vitro using
synthetic mycolactone as a standard show that MS can detect
mycolactone at a concentration of less than 10 pg/ml so it is more
likely that some cytotoxicity was caused by other lipid molecules
generated during the course of M. ulcerans infection. Nevertheless
this evidence that mycolactone may have persisted in mouse tissue
well after antibiotics had started to reduce the burden of infection
Figure 5. Cytotoxic activity of lipids extracted from footpads of mice without treatment or treated with rifampin-streptomycin.
Cytotoxicity of lipid extracts was measure by the MTT assay after incubation with HELF cells for 48 hrs. Cytotoxicity is expressed relative to that
induced by synthetic mycolactone measured concurrently. Data based on 3 mice per group per time point. By day 63 there were statistically
significant differences between the infected right hind footpad (RHFP, black solid circles) and the contralateral (LHFP, solid diamonds, p,0.02) and
footpads of the rifampin-streptomycin (Abx) treated mice (RHFP, red open circles; LHFP, red open diamonds p,0.05).
doi:10.1371/journal.pntd.0002101.g005
Buruli Ulcer Mouse Model: Mycolactone & Pathology
PLOS Neglected Tropical Diseases | www.plosntds.org 8 March 2013 | Volume 7 | Issue 3 | e2101
Buruli Ulcer Mouse Model: Mycolactone & Pathology
PLOS Neglected Tropical Diseases | www.plosntds.org 9 March 2013 | Volume 7 | Issue 3 | e2101
when footpad swelling was diminishing is important in the context
of human infection in which slow healing has been observed in
some cases without an obvious reason.
Mycolactone has profound effects on the production of
cytokines and chemokines in vitro even at sub-cytotoxic concen-
tration and this may well influence the rate of wound healing. In
the present experiments for example, TNF-a production by
splenocytes increased in response to mycobacterial antigens during
M. ulcerans infection but this reverted to normal during antibiotic
treatment. A similar but delayed and relatively attenuated
response was observed for other cytokines such as IFN-c, IL-5,
and IL-17. ConA, a potent mitogen, assessed the capacity of
splenocytes to produce cytokines upon stimulation, while the Mtb
CFP elicited responses to mycobacterial antigens but is not specific
for M. ulcerans. The initial rise in the secretion of cytokines
coincides with the infiltration of host inflammatory cells and the
intracellular stage of M. ulcerans when mycolactone concentrations
were low. Subsequently mycolactone concentrations start to build
up at the site of infection, M. ulcerans assumes an extracellular
localization and prevents antigen-presenting cells from processing
mycobacterial antigens for a systemic immune response. The fact
that M. ulcerans assumes an extracellular localization and that
mycolactone concentrations begin to increase locally could
prevent antigen presenting cells from processing M. ulcerans for
systemic immune responses to develop [40]. Again Hong et al.
[41] have shown that mycolactone A/B could be detected in
PBMC’s of mice infected with M. ulcerans and indeed recently ML
has been detected in sera of some human’s infected with M. ulcerans
[42]. The later recovery of systemic cytokine secretion in the light
of increasing concentrations of mycolactone locally in the footpads
is difficult to explain. In the proximal phases of M. ulcerans
infection, this initial exposure may be inhibited by increasing
bacillary load and the production of mycolactone. Subsequently,
the splenocytes could encounter and process mycobacterial
antigens released into the circulation or conveyed from the site
of infection in the later stages of M. ulcerans infection from
degradation of defunct M. ulcerans in mice treated with bactericidal
antibiotics (Figure 4, both columns).
Some patients are able to control M. ulcerans infections at the
early nodular stage without antibiotics and these data may provide
some insight into why this might be the case. It would seem that
those with robust immune responses, a lower burden of M. ulcerans
and thus mycolactone secretion initially may be able to contain the
M. ulcerans infection. Further studies are, however, required to
elucidate the correlations between local and systemic mycolactone
kinetics in tandem with immune responses in these two
compartments in this model.
The finding that cytotoxicity was increased in contra-lateral
footpads well away from the site of infection remains difficult to
explain. Mycolactone molecules were not detected by MS but we
cannot rule out the possibility that cytotoxic breakdown products
of mycolactone, or other molecules, circulated to these footpads.
Other studies have shown that mycolactone itself was detectable in
peripheral blood white cells during mouse infection with M.
ulcerans [41].
Further studies may focus on the determination of cytokines in
the milieu of the footpad lesion in mice before and after treatment
with the current regimen or a new all oral regimen, such as one
replacing streptomycin with clarithromycin, as well as the impact
of vaccination on mycolactone production and local immunity
after footpad challenge. Refinements in calculating the amount of
mycolactone obtained after extraction may be made by spiking
different concentrations of synthetic mycolactone into uninfected
footpads and determining the linearity of the yield.
Author Contributions
Conceived and designed the experiments: FSS PJC DVA MWJ JHG.
Performed the experiments: PJC DVA FSS JZ CR. Analyzed the data: PJC
FSS. Contributed reagents/materials/analysis tools: PJC FSS DVA JZ CR.
Wrote the paper: PJC FSS MWJ JHG.
References
1. Converse PJ, Nuermberger EL, Almeida DV, Grosset JH (2011) Treating
Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill
mightier than the knife? Future Microbiology 6: 1185–1198.
2. Amofah G, Bonsu F, Tetteh C, Okrah J, Asamoa K, et al. (2002) Buruli ulcer in
Ghana: results of a national case search. Emerg Infect Dis 8: 167–170.
3. Sopoh GE, Johnson RC, Chauty A, Dossou AD, Aguiar J, et al. (2007) Buruli
ulcer surveillance, Benin, 2003–2005. Emerg Infect Dis 13: 1374–1376.
4. Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J (2002) Bactericidal activity
of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents
Chemother 46: 3193–3196.
5. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999)
Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for
virulence. Science 283: 854–857.
6. Krieg RE, Hockmeyer WT, Connor DH (1974) Toxin of Mycobacterium ulcerans.
Production and effects in guinea pig skin. Arch Dermatol 110: 783–788.
7. Read JK, Heggie CM, Meyers WM, Connor DH (1974) Cytotoxic activity of
Mycobacterium ulcerans. Infect Immun 9: 1114–1122.
8. Walsh DS, Portaels F, Meyers WM (2011) Buruli ulcer: Advances in
understanding Mycobacterium ulcerans infection. Dermatol Clin 29: 1–8.
9. Silva MT, Portaels F, Pedrosa J (2009) Pathogenetic mechanisms of the
intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect
Dis 9: 699–710.
10. Ruf M-T, Sopoh GE, Brun LV, Dossou AD, Barogui YT, et al. (2011)
Histopathological Changes and Clinical Responses of Buruli Ulcer Plaque
Lesions during Chemotherapy: A Role for Surgical Removal of Necrotic Tissue?
PLoS Negl Trop Dis 5: e1334.
11. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, et al. (2011)
Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combina-
tion against Mycobacterium ulcerans Disease in Mice. PLoS Negl Trop Dis 5: e933.
12. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, et al. (2001) Activities of
new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in
mice. Antimicrob Agents Chemother 45: 3109–3112.
13. Lefrancois S, Robert J, Chauffour A, Ji B, Jarlier V (2007) Curing Mycobacterium
ulcerans infection in mice with a combination of rifampin-streptomycin or
rifampin-amikacin. Antimicrob Agents Chemother 51: 645–650.
14. Pettit JHS, Marchette NJ, Rees RJW (1966) Mycobacterium ulcerans infection.
Clinical and bacteriological study of the first cases recognized in South East Asia.
British Journal of Dermatology 78: 187–197.
Figure 6. Mycolactone detection by mass spectrometry in mouse footpads. A. EPI Mass spectra indicated a propensity of authentic
mycolactone A/B to form a sodium adduct (m/z 765.7, [M+Na+]). Fragment ions at m/z 429.6 and 359.5 correspond to the core lactone and
polyketide side chains, respectively. B. Mycolactone A/B detected in footpad extracts displayed similar mass spectra and also contained a number of
other ions (e.g. m/z 659.6 and 747.7) that were present in authentic reference material. C and D. Extracted ion chromatograms (XIC) for m/z 429.6,
which was selected for quantification in LC-MRM analyses of tissue extracts. Standard mycolactone is shown in C and a footpad sample in D. The
sensitivity of the assay (,10 pg) was such that it was possible to measure mycolactone in the tissue samples. E. Mycolactone (ML) was detectable as
early as day 13 after infection and before the onset of visible swelling in mouse footpads. No ML was detectable in the contralateral footpad of either
the RIF-STR-treated or the untreated control mice. Data based on pooled lipid extracts from 3 mice per group per time point.
doi:10.1371/journal.pntd.0002101.g006
Buruli Ulcer Mouse Model: Mycolactone & Pathology
PLOS Neglected Tropical Diseases | www.plosntds.org 10 March 2013 | Volume 7 | Issue 3 | e2101
15. Converse PJ, Almeida DV, Nuermberger EL, Grosset JH (2011) BCG-Mediated
Protection against Mycobacterium ulcerans Infection in the Mouse. PLoS Neglected
Tropical Diseases 5: e985.
16. Zhang T, Li S-Y, Converse PJ, Almeida DV, Grosset JH, et al. (2011) Using
Bioluminescence To Monitor Treatment Response in Real Time in Mice with
Mycobacterium ulcerans Infection. Antimicrob Agents Chemother 55: 56–61.
17. Shepard CC (1967) A kinetic method for the study of the activity of drugs against
Mycobacterium leprae. Int J Lepr 35: 429–436.
18. Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J (2000) Activities of several
antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents
Chemother 44: 2367–2372.
19. Mve-Obiang A, Lee RE, Portaels F, Small PL (2003) Heterogeneity of
mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications
for virulence. Infect Immun 71: 774–783.
20. Marsollier L, Brodin P, Jackson M, Kordulakova J, Tafelmeyer P, et al. (2007)
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches
and Buruli ulcer pathogenesis. PLoS Pathog 3: e62.
21. Sarfo FS, Phillips RO, Rangers B, Mahrous EA, Lee RE, et al. (2010) Detection
of Mycolactone A/B in Mycobacterium ulcerans–Infected Human Tissue. PLoS
Negl Trop Dis 4: e577.
22. Schu¨tte D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P, et al. (2007)
Development of highly organized lymphoid structures in Buruli Ulcer lesions after
treatment with rifampicin and streptomycin. PLoS Neglected Tropical Diseases 1: e2.
23. Schu¨tte D, UmBoock A, Pluschke G (2009) Phagocytosis of Mycobacterium ulcerans
in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer
lesions. British Journal of Dermatology 160: 273–283.
24. Martins TG, Gama JB, Fraga AG, Saraiva M, Silva MT, et al. (2012) Local and
Regional Re-Establishment of Cellular Immunity during Curative Antibiother-
apy of Murine Mycobacterium ulcerans Infection. PLoS ONE 7: e32740.
25. Ruf MT, Schutte D, Chauffour A, Jarlier V, Ji B, et al. (2012) Chemotherapy-
associated changes of histopathological features of Mycobacterium ulcerans lesions in
a Buruli ulcer mouse model. Antimicrob Agents Chemother 56: 687–696.
26. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, et al. (2007)
Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect
Immun 75: 977–987.
27. Connor DH, Lunn HF (1965) Mycobacterium ulcerans infection (with comments on
pathogenesis). Int J Lepr 33: Suppl:698–709.
28. Connor DH, Lunn HF (1966) Buruli Ulceration: a clincopathologic study of 38
Ugandans with Mycobacterium ulcerans ulceration. Arch Path 81: 183–199.
29. Connor DH, Meyers WM, Krieg RE (1976) Infection by Mycobacterium ulcerans.
In: Binford CH, Connor DH, editors. Pathology of Tropical and Extraordinary
Diseases. Washington, D.C.: Armed Forces Institute of Pathology. pp. 226–235.
30. Ramakrishnan L (1997) Images in clinical medicine. Mycobacterium marinum
infection of the hand. N Engl J Med 337: 612.
31. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, et al. (2005)
Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune
response and cellular location of M. ulcerans in vitro and in vivo. Cellular
Microbiology 7: 1295–1304.
32. En J, Goto M, Nakanaga K, Higashi M, Ishii N, et al. (2008) Mycolactone is
responsible for the painlessness of Mycobacterium ulcerans infection (Buruli ulcer) in
a murine study. Infect Immun 76: 2002–2007.
33. Goto M, Nakanaga K, Aung T, Hamada T, Yamada N, et al. (2006) Nerve
Damage in Mycobacterium ulcerans-Infected Mice: Probable Cause of Painlessness
in Buruli Ulcer. Am J Pathol 168: 805–811.
34. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, et al. (2005)
Infection with Mycobacterium ulcerans Induces Persistent Inflammatory Responses
in Mice. Infect Immun 73: 6299–6310.
35. Torrado E, Adusumilli S, Fraga AG, Small PLC, Castro AG, et al. (2007)
Mycolactone-mediated inhibition of tumor necrosis factor production by
macrophages infected with Mycobacterium ulcerans has implications for the control
of infection. Infect Immun 75: 3979–3988.
36. Peduzzi E, Groeper C, Schu¨tte D, Zajac P, Rondini S, et al. (2007) Local
activation of the innate immune system in Buruli ulcer lesions. J Invest Dermatol
127: 638–645.
37. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, et al. (2005)
Modulation of the host immune response by a transient intracellular stage of
Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin.
Cellular Microbiology 7: 1187–1196.
38. Martins TG, Trigo G, Fraga AG, Gama JB, Longatto-Filho A, et al. (2012)
Corticosteroid-Induced Immunosuppression Ultimately Does Not Compromise
the Efficacy of Antibiotherapy in Murine Mycobacterium ulcerans Infection. PLoS
Negl Trop Dis 6: e1925.
39. Beissner M, Symank D, Phillips RO, Amoako YA, Awua-Boateng N-Y, et al.
(2012) Detection of Viable Mycobacterium ulcerans in Clinical Samples by a Novel
Combined 16S rRNA Reverse Transcriptase/IS2404 Real-Time qPCR Assay.
PLoS Negl Trop Dis 6: e1756.
40. Fraga AG, Cruz A, Martins TG, Torrado E, Saraiva M, et al. (2011)
Mycobacterium ulcerans Triggers T-Cell Immunity followed by Local and Regional
but Not Systemic Immunosuppression. Infect Immun 79: 421–430.
41. Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadlay PF, et al. (2008)
Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets
mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop
Dis 2: e325.
42. Sarfo FS, Le Chevalier F, Aka NG, Phillips RO, Amoako Y, et al. (2011)
Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients -
Implications for Diagnosis and Disease Monitoring. PLoS Negl Trop Dis 5:
e1237.
Buruli Ulcer Mouse Model: Mycolactone & Pathology
PLOS Neglected Tropical Diseases | www.plosntds.org 11 March 2013 | Volume 7 | Issue 3 | e2101
